Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE002619 |
ID: | TCMBANKHE002619 |
药用植物名: | 猴枣 |
治疗类型: | 化痰药 |
SymMap_id: | 170 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN009083 | agrimonicacid b | C48H32O31 | |||
| TCMBANKIN011151 | (+)-2-N-Methylfangchinoline | (+)-2-n-methylfangchinoline | 623.83 | CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CC[N+]6(C)C)OC)O)OC)OC | |
| TCMBANKIN014396 | 3-[2-[[3-(2-carboxyethyl)-4-methyl-5-[(E)-(4-methyl-5-oxo-3-vinyl-2-pyrrolylidene)methyl]-1H-pyrrol-2-yl]methyl]-4-methyl-5-[(E)-(3-methyl-5-oxo-4-vinyl-2-pyrrolylidene)methyl]-1H-pyrrol-3-yl]propanoic acid | 3-[2-[[3-(2-carboxyethyl)-5-[(E)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(E)-(4-ethenyl-3-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid; 3-[2-[[3-(2-carboxyethyl)-5-[(E)-(5-keto-4-methyl-3-vinyl-3-pyrrolin-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(E)-(5-keto-3-methyl-4-vinyl-3-pyrrolin-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propionic acid; 3-[2-[[3-(2-carboxyethyl)-5-[(E)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(E)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid; 3-[2-[[3-(2-carboxyethyl)-4-methyl-5-[(E)-(4-methyl-5-oxo-3-vinyl-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl]methyl]-4-methyl-5-[(E)-(3-methyl-5-oxo-4-vinyl-pyrrol-2-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid | C33H36N4O6 | 584.66 | |
| TCMBANKIN015294 | tormenticacid-6-methoxy β-d-glucopyranosylester | CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)O)O)C)C)C2C1(C)O)C)C(=O)OC6C(C(C(C(O6)COC)O)O)O | |||
| TCMBANKIN017993 | vitamin c | D01CWN; Cell C; Ronotec 100; P 1110; Suncoat VC 40; D-threo-hex-2-enoic acid gamma-lactone; Citrovit; 2-o-(beta-d-glucopyranosyl)-ascorbic acid_qt; Juvamine; SCHEMBL13468284; Vasc; CHEBI:51384; D-Lyxoascorbic acid; CHEMBL1253320; AK481251; Chewcee; D-xyloascorbic acid; C8DQ5M1Y1E; MLS001066386; AK322241; Ascorbic acid, D-; AC1LD8K5; E 300; Scorbu C; 10504-35-5; Ascorbicacid; l(+)-ascorbic acid; ZINC100006137; L-ascorbate (vitamin C); (5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; (+)-Ascorbic acid; UNII-C8DQ5M1Y1E; Ascorbinsaure; Ceklin; VC 97; (2S)-2-[(1R)-1,2-bis(oxidanyl)ethyl]-4,5-bis(oxidanyl)furan-3-one; Vicin; L-ascorbate acid; L-ascorbic acid; L-dehydroascorbic acid; ascorbate; D-threo-hex-2-enono-1,4-lactone; Kangbingfeng; D-Ascorbic acid; Viscorin 100M; ZINC100028197; (2S)-2-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxy-3-furanone; L-Ascorbic acid (8CI,9CI); Proscorbin Redoxon Ribena Ronotec 100; Hex-2-enonic acid gamma-lactone, L-threo; (5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxy-2,5-dihydrofuran-2-one; Ascorbic acid; DL-Ascorbic acid; AKOS000278050; Cebion, gamma-lactone; F91F7DA3-A3D5-4FB4-A6E7-C497C48D192A; GTPL4651; SMR000471843; Xyloascorbic acid, L-; Rontex 100; Rovimix C; (2S)-2-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; A828310 | C6H8O6 | 176.12 | C(C(C1C(=C(C(=O)O1)O)O)O)O |
| TCMBANKIN025494 | agrimonicacid a | C48H32O31 | |||
| TCMBANKIN032992 | Methyl trametenolate | methyl trametenolate | C31H50O3 | 470.7 g/mol | CC(=CCCC(C1CCC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)O)C)C)C)C(=O)OC)C |
| TCMBANKIN036802 | ellagic acid | 2,3,7,8-Tetrahydroxy(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,10-dione; 4,4',5,5',6,6'-hexahydroxydiphenic acid 2,6,2',6'-dilactone; CE0034; 5-19-07-00108 (Beilstein Handbook Reference); AS-12615; ellagic acid ; LTK-20; 133039-73-3; ellagicacid; NE58729; 2,3,7,8-Tetrahydroxy(1)benzopyrano(5,4,3-cde)-(1)benzopyran-5,10-dione; AIDS002688; Spectrum3_001535; SBB006501; 4,4′,5,5′,6,6′-Hexahydroxydiphenic acid 2,6,2′,6′-dilactone; Llagic acid; BRN 0047549; 2,6,2',6'-dilactone hydrate; 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; KBio2_004242; Polyphenolic; NCGC00094975-01; Eleagic acid; MFCD00149494; MolPort-000-705-556; 2,3,7,8-tetrahydroxy[1]benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione; [1]Benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione, 2,3,7,8-tetrahydroxy-; EINECS 207-508-3; NCGC00017245-01; NCI60_003869; Ellagsaeure; Ellagic Acid, Dihydrate; Diphenic acid, 4,4',5,5',6,6'-hexahydroxy-, di-.delta.-lactone; KBio3_002450; MLS-0066664.0001; KBio2_006810; SCHEMBL2639621; Ellagic acid hydrate, 97%, may cont. up to 12% water; Ellagic acid dihydrate; 6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.0,(1).0(1)(1),(1)]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione dihydrate; Spectrum2_000905; Gallogen (astringent); TNP00132; KBioSS_001674; MLS000069632; SMP1_000111; (1)Benzopyrano(5,4,3-cde)(1)benzopyran-5,10-dione, 2,3,7,8-tetrahydroxy-; BSPBio_002950; Oprea1_032884; C.I. 75270; NSC656272; SPBio_000750; NSC 656272; BCBcMAP01_000154; Elagostasine; I14-61927; NSC 407286; BB_NC-0491; C10788; C.I. 55005; 2,3,7,8-Tetrahydroxy[1]benzopyrano-[5,4,3-cde][1]benzopyran-5,10-dione; Spectrum_001194; Gallogen, astringent; SMR000058244; CHEBI:4775; SPECTRUM1502245; KBio2_001674; KBioGR_001080; 6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.0^{4,16}.0^{11,15}]hexadeca-1(15),4(16),5,7,11,13-hexaene-3,10-dione dihydrate; Acido elagico [INN-Spanish]; BG00667714; 476-66-4; Benzoaric acid; AK186482; SDCCGMLS-0066664.P001; Z1551861526; CCRIS 774; Gallogen (VAN); NSC407286; Ellagic acid [DCF:INN]; [1,1'-Biphenyl]-2,2'-dicarboxylic acid, 4,4',5,5',6,6'-hexahydroxy-, di-.delta.-lactone; CCG-208140; NCGC00094975-02; 4,4′,5,5′,6,6′-Hexahydroxydiphenic Acid 2,6,2′,6′-Dilactone; Spectrum4_000750; Alizarine Yellow; 6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.0?,??.0??,??]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione dihydrate; Diphenic acid, 4,4',5,5',6,6'-hexahydroxy-, di-delta-lactone; AIDS-002688; AKOS025310087; Acidum ellagicum [INN-Latin]; Lagistase; ZINC00058174; C14H6O8.2H2O; Spectrum5_000959; E2250_SIGMA; Acide ellagique [INN-French]; NCGC00094975-03; 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione dihydrate; Ellagic acid | C14H6O8 | 302.193 | c1(O[H])c([H])c2c(c(c(C(=O)O3)c([H])c(O[H])c4O[H])c4OC2=O)c3c1O[H] |
| TCMBANKIN039925 | rosamultin | CHEMBL501885; [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl] (1R,2R,4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-1,10,11-trihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate; .beta.-D-Glucopyranose, 1-O-[(2.alpha.,3.beta.)-2,3,19-trihydroxy-28-oxours-12-en-28-yl]-; rosamultin ; ZINC67902677; 88515-58-6; Rosamultin; Rosamutin | C36H58O10 | 651 | [C@@]1([H])(C([H])([H])[H])[C@@](C([H])([H])[H])(O[H])[C@@]([H])(C(=C([H])C([H])([H])[C@]([H])([C@@](C([H])([H])[H])(C([H])([H])[C@@]([H])(O[H])[C@@]([H])(O[H])C2(C([H])([H])[H])C([H])([H])[H])[C@@]2( [H])C([H])([H])C3([H])[H])[C@@]34C([H])([H])[H])[C@@]4(C([H])([H])[H])C([H])([H])C5([H])[H])[C@]5(C(=O)O[C@@]6([H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(C([H])([H])O[H])O6)C([H])([H ])C1([H])[H] |
| TCMBANKIN041536 | potentillin | C41H28O26 | 936.6 g/mol | C1C2C(C3C(C(O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5C6=C(C(=C(C=C6C(=O)O3)O)O)O)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O | |
| TCMBANKIN043119 | methyl 2α-methoxyursolate | methyl 2alpha-methoxyursolate | CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)O)OC)C)C)C2C1C)C)C(=O)OC | ||
| TCMBANKIN043314 | 7-oxositosteryl-β-o-glucopyranoside | CCC(CCC(C)C1CCC2C1(CCC3C2C(=O)C=C4C3(CCC(C4)OC5C(C(C(C(O5)CO)O)O)O)C)C)C(C)C | |||
| TCMBANKIN044899 | Methyl 11α-hydroxytormentate | methyl 11alpha-hydroxytormentate; AC1NSYG4; methyl (12aS)-1,10,11,13-tetrahydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate | |||
| TCMBANKIN049259 | Methyl 2α-hydroxyursa-28-oate | ||||
| TCMBANKIN058062 | sanguiinh4 | sanguiin h4 | C27H22O18 | 634.5 g/mol | C1=C(C=C(C(=C1O)O)O)C(=O)OC2C3C(C(C(O2)CO)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O3)O)O)O)O)O)O |
| TCMBANKIN058267 | vitamin b | NSC169454; SR-01000722017-4; Nicotinic acid, >=98%; [3H]nicotinic acid; Nicotinamide (JP15/INN); AC1Q73P3; C6H5NO2; 11054-EP2289510A1; NCGC00094734-02; AB00052050; HMS3655K08; Efacin; Nico-400; N1103; 11054-EP2298772A1; TR-032523; C00253; Nicosan 3; SPBio_000011; Nicotinic Acid [Matrix for MALDI-TOF/MS]; SPBio_002881; 5-22-02-00057 (Beilstein Handbook Reference); Niacinamide Astra Brand; Spectrum3_000515; ANW-75276; Bionic; 11054-EP2301923A1; SDCCGMLS-0066610.P001; Nicotinsaure [German]; Nicotinic acid, >=99.5% (HPLC); preventative factor; 28029-53-0 (cobalt(2+) salt); SR-01000722017-3; Acide nicotinique [INN-French]; 11054-EP2295409A1; NICO; InChI=1/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9; D00049; Jenapharm Brand of Niacinamide; Nicotinamide (TN); Niacin [USAN]; bmse000104; 1976-28-9 (aluminum salt); 11054-EP2311816A1; Apelagrin; AN-23622; KBio2_001543; ABT-919; Acido nicotinico; .beta.-Pyridinecarboxylic acid; Niaspan (TN); 11054-EP2270002A1; SR-01000722017-2; KB-33243; Pellagramin; NCGC00016268-02; DSSTox_CID_932; Merck Brand of Niacinamide; nicobid; beta-pyridinecarboxylic acid; BDBM23515; 3PyrCOOH; Nicotinic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=98%; Pellagra preventive factor; niacin; Prestwick0_000881; Nicotinic acid, Ph Eur; BPBio1_000730; Nicacid; UNII-2679MF687A; EBD2198325; NCGC00016268-08; 3-Carboxypyridine; ST097540; Z56755709; Davitamon PP; Nicotinamide (Niacinamide); Nicotinic acid, analytical standard; CPD000059024; 3-Pyridylcarboxylic acid; Pyridine-beta-carboxylic acid; KBioSS_001543; 11054-EP2305674A1; Nicotinic acid, for synthesis, 99%; Nicodon; Oprea1_514398; [5, 6-3H]-niacin; 636-79-3 (hydrochloride); Direktan; Niacin (Nicotinic Acid), Pharmaceutical Secondary Standard; Certified Reference Material; DB-007765; 11054-EP2298742A1; Nyclin; 11054-EP2316827A1; NSC-169454; 7069-06-9 (magnesium salt); 11054-EP2316826A1; Niacor; niacine; MLS000069603; AC-907/25014105; GTPL1594; Spectrum5_001287; RP00705; niacin potassium; BSPBio_002069; STR00112; IDI1_000695; LS-2334; AM81316; NAH; P.P. factor-pellagra preventive factor; AC-22484; Vitaplex N; Nicodan; 3789-96-6 (tartrate); 11054-EP2311829A1; AB1002056; Niacinamide Merck Brand; Spectrum4_000965; Pyridinecarboxylic acid, 3-; CCRIS 1902; 11054-EP2308838A1; SBI-0051456.P003; 11054-EP2280001A1; Nicotinic acid [INN]; PubChem2594; Nicovasen; 54-86-4 (hydrochloride salt); 11054-EP2274983A1; 11054-EP2308854A1; NCGC00016268-04; MCULE-3788394698; Nicagin; nicolar; NIASPAN TITRATION STARTER PACK; AB00052050-13; ST2413625; J-523605; 36321-41-2 (ammonium salt); Acido nicotinico [INN-Spanish]; Akotin; EINECS 200-441-0; SBB004279; 11054-EP2311830A1; Niacin, United States Pharmacopeia (USP) Reference Standard; Acidum nicotinicum; Nikasan; SR-01000722017; AK-46486; Enduracin; CS-1946; Nicotinic acid, certified reference material, TraceCERT(R); Induracin; Nico-Span; antipellagra vitamin; 3-pyridine carboxylic acid; Nicoside; Nicotinic acid, purum, >=99.0% (HPLC); CHEMBL573; Pyridylcarboxylic Acid; Tinic; 11054-EP2295424A1; EPA Pesticide Chemical Code 056701; Nicotine acid; Ncotnc acd; 11054-EP2305651A1; pellagra; Nicorol; 5-pyridinecarboxylic acid; NCGC00094734-01; 11054-EP2298776A1; 3-Picolinic acid; Niacin; Pellagra preventive factor; Pyridine-3-carboxylic acid; Vitamin B3; KBioGR_001309; 11054-EP2308848A1; KSC236Q9T; Nipellen; Niacin (USP); 3-pyridinecarboxylic acid; Vitamin B3 (Niacin); KBio2_006679; NCI60_001041; HMS2236A05; AB00052050_14; Nicotinic acid, matrix substance for MALDI-MS, >=99.5% (HPLC); HMS2097B04; Spectrum2_000006; 99148-57-9 (tosylate); SCHEMBL1433; BSPBio_000662; MolPort-000-142-273; KBio3_001569; 10361-13-4 (iron(2+) salt); Tox21_110337_1; F2191-0082; Acide nicotinique; Nicotinic acid, European Pharmacopoeia (EP) Reference Standard; 11054-EP2269990A1; 11054-EP2308858A1; M-5918; 11054-EP2275401A1; Nicotinic acid, plant cell culture tested; Nicotinic acid, SAJ special grade, >=99.5%; Niacinamide (TN); HMS3714B04; STK301803; Pelonin; Niconazid; Prestwick2_000881; Nicovasan; 11054-EP2270014A1; Niacinamide Pharmagenix Brand; Pharmakon1600-01500430; Pyridine-carboxylique-3 [French]; SK-Niacin; Prestwick1_000881; Nikazan; EC 200-441-0; PP Factor; AKOS000118980; HY-B0143; Tox21_110337; HMS3371E07; WLN: T6NJ CVQ; Nicotene; Nicotinic acid [INN:BAN]; CAS-59-67-6; 11054-EP2316458A1; Kyselina nikotinova [Czech]; P.P. factor; Pyridine-3-carboxylic acid; Niacin (nicotinic acid); Tox21_201420; L001199; NCGC00016268-09; nicocap; I02-0699; nicotinic acid; Niconat; ZINC1795; Niacin [USP]; Diacin; 11054-EP2272825A2; Kyselina nikotinova; FC1287; Nicotinic acid-d3(major); CHEBI:15940; 823-77-8 (calcium salt); Niacor (TN); DSSTox_RID_75875; NCGC00256537-01; Nicotamin; GTPL1588; 2679MF687A; ACMC-1AS6M; [3H]-Nicotinic acid; SPECTRUM1500430; Acidum nicotinicum [INN-Latin]; HMS1570B04; 11054-EP2301937A1; KBio1_000695; BP-21419; Niacinamide Jenapharm Brand; AJ-08093; Nicotinic acid, NIST(R) SRM(R) 148; niacin magnesium; Nicyl; S115; Tega-Span; 11054-EP2269610A2; KBio2_004111; AC1L1AD5; NCGC00016268-01; Niacinamide, Nicotinic acid amide, Nicotinamide; Opera_ID_1346; Nicotinic acid, 99% 250g; 3-Pyridyl carboxylic acid; Nicocidin; nicotinate; s1744; SR 4390; DTXSID1020932; Nicotinsaure; 16518-17-5 (potassium salt); Nicotinic acid, Vetec(TM) reagent grade, >=98%; 11054-EP2308839A1; Linic; BIDD:GT0644; NC00524; wampocap; NCGC00016268-03; Nicotinic acid, for inorganic trace analysis, >=99.999% (metals basis); AB00052050_15; Nicosyl; CCG-38340; D06NVJ; 11054-EP2301935A1; 11054-EP2308874A1; Nikotinsaeure; SC-05611; Pyridine-3-carbonic acid; Nicodelmine; 53890-72-5 (lithium salt); 11054-EP2311808A1; SMR000059024; Daskil; NSC 169454; MFCD00006391; PS-4255; HMS502C17; 11054-EP2272848A1; FT-0082580; Pyridine-.beta.-carboxylic acid; DivK1c_000695; 11054-EP2295406A1; Niacin-Vitamin B3; N0082; BRN 0109591; 3-Carboxylpyridine; 11054-EP2316828A1; Niac; NCGC00258971-01; 3-Picolinic acid; 11054-EP2292610A1; NINDS_000695; 11054-EP2292228A1; FT-0600004; Astra Brand of Niacinamide; Nicotinic Acid 1.0 mg/ml in Methanol; 11054-EP2272834A1; HMS3259K21; Niacin (TN); Nicotinic acid (JP17/INN); NSC-757241; Prestwick3_000881; Niaspan; Slo-niacin; SAM002554917; HMS2091H22; Pharmagenix Brand of Niacinamide; 59-67-6; NCGC00016268-05; Tox21_302904; Pellagrin; Caswell No. 598; 11054-EP2277848A1; 3DDB011E-F3A6-45B6-A2D2-77B2A6E8936E; 11054-EP2301929A1; 11054-EP2311817A1; Naotin; m-Pyridinecarboxylic acid; vitamin B3; HSDB 3134; Peviton; nicamin; Nicotinic acid (Vitamin B3) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Nicangin; Spectrum_001063; Pyridine-carboxylique-3; KB-259513; 11054-EP2298779A1; Nicocrisina; DB00627; 11054-EP2316825A1; AI3-18994; PVNIIMVLHYAWGP-UHFFFAOYSA-N; 11054-EP2316457A1; I14-92791; anti-Pellagra vitamin; 28029-54-1 (manganese(2+) salt); NSC757241; 123574-58-3; Nicotil; HMS1920P17; Nicotinipca; 3-Pyridinecarboxylicacid; 11054-EP2314588A1; Niconacid; NIO; Nicotinic acid, meets USP testing specifications; DSSTox_GSID_20932; Nicotinamide-carbonyl-14C | C5H4NCOOH | 123.11 g/mol | C1=CC(=CN=C1)C(=O)O |
| TCMBANKIN059337 | CHD;cholalic acid;cholicacid | 5beta-Cholanic acid, 3alpha,7alpha,12alpha-trihydroxy- (7CI); cholic acid; 3alpha,7alpha,12alpha-Trihydroxycholanic acid; 81-25-4 (FREE ACID); CHOLATE; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanoic acid; (3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxycholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-beta-cholanic acid; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; Colalin; C9377_SIGMA; SMR000112165; 3.alpha.,7.alpha.,12.alpha.-Trihydroxy-5.beta.-cholanic acid; AIDS017669; 5.beta.-Cholan-24-oic acid, 3.alpha.,7.alpha.,12.alpha.-trihydroxy-; MLS001066422; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3alpha,5beta,7alpha,12alpha)- (9CI); AIDS-017669; Cholic acid (8CI); Cholalic acid; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3-alpha,5-beta,7-alpha,12-alpha)-; Cholsaeure; C1129_SIGMA; ST024722; Spectrum5_002005; 5beta-Cholanic acid-3alpha,7alpha,12alpha-triol 5beta-Cholic acid; Cholalin; 17beta-[1-Methyl-3-carboxypropyl]etiocholane-3alpha,7alpha,12alpha-triol; 73163-53-8 (NA SALT); NSC-6135; 81-25-4; 3-&alpha,7-&alpha,12-&alpha-trihydroxy-5-&beta-cholanate; (3.alpha.,5.beta.,7.alpha.,12.alpha.)-3,7,12-Trihydroxycholan-24-oic acid sodium salt; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid; NSC6135; CHEBI:16359; C00695; LMST04010001;cholic acid;cholic acid | C24H40O5 | 408.57;408.6 g/mol | CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C |
| TCMBANKIN060529 | Tormentic acid | C30H48O5 | 488.7 g/mol | CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)O)O)C)C)C2C1(C)O)C)C(=O)O | |
| TCMBANKIN060530 | methyl euscaphate | C31H50O5 | 502.7 g/mol | CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)O)O)C)C)C2C1(C)O)C)C(=O)OC | |
| TCMBANKIN060533 | Methyl 2alpha-hydroxyursolate | C31H50O4 | 486.81 | CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)O)O)C)C)C2C1C)C)C(=O)OC | |
| TCMBANKIN060537 | Euscaphic acid 3,4-monoacetonide | C30H48O5 | 488.7 | CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC6C(C5(C)C)OC(O6)(C)C)C)C)C2C1(C)O)C)C(=O)O |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab